ABC transporter inhibitors such as β-caryophyllene oxide have been shown to sensitize HCC cells to sorafenib by favoring its intracellular accumulation [224], but these compounds are still in development and their clinical utility is still unknown. This evidence concerns the gene ABCG2 and hepatocellular carcinoma.